microRNA and Down Syndrome
microRNA 和唐氏综合症
基本信息
- 批准号:7922543
- 负责人:
- 金额:$ 22.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-01 至 2011-12-31
- 项目状态:已结题
- 来源:
- 关键词:21q3&apos Untranslated RegionsActivities of Daily LivingAddressAdultAgeAttenuatedBase PairingBinding SitesBioinformaticsBloodBrainBrain regionCREB1 geneCell LineChildChromosome abnormalityChromosomes, Human, Pair 21CodeCognitiveCognitive deficitsComplexCongenital AbnormalityCongenital Heart DefectsCraniofacial AbnormalitiesDataDefectDisadvantagedDown SyndromeDown-RegulationDysplasiaFamilyFamily health statusFigs - dietaryFutureGene ExpressionGene TargetingGenesGeneticHealthcare SystemsHeartHereditary DiseaseHumanHuman ChromosomesImpaired cognitionIn Situ HybridizationIncidenceIndividualInjection of therapeutic agentKnowledgeLeadLive BirthMessenger RNAMethyl-CpG-Binding Protein 2MicroRNAsMolecularMolecular ProfilingMusMutationNeoplasmsNeurodegenerative DisordersNeurodevelopmental DisorderNeurologicNeuronal PlasticityNeuropathogenesisPathogenesisPatientsPenetrancePerinatalPhenotypePlayPopulationProteinsQuality of lifeRNA DegradationRegulationRegulator GenesRelative (related person)RepressionResearchRett SyndromeReverse Transcriptase Polymerase Chain ReactionRoleSecondary toSiteSpecimenSyndromeTestingTherapeutic InterventionTranscriptTranslationsUnited StatesUntranslated RegionsVentricularbasecare burdenclinically relevantcombinatorialfetalgastrointestinalgenetic regulatory proteinhuman tissuein vivoinnovationknock-downmouse modelneurodevelopmentneuron developmentnovelnovel therapeuticsprotein expressionpublic health relevanceresearch studysextranscription factor
项目摘要
DESCRIPTION (provided by applicant): The chromosome abnormality in Down syndrome (DS) results from a triplication in a portion of human chromosome 21 (Hsa21), but how this chromosomal anomaly causes the DS phenotype is not clear. The current proposal will directly address this issue, with an emphasis on a novel class of endogenous gene regulators, microRNAs (miRNAs). MiRNAs are generally regarded as negative regulators of gene expression that inhibit translation and/or promote messenger RNA (mRNA) degradation by base-pairing to complementary sequences within protein-coding mRNA transcripts. Our recent bioinformatic analyses established that Hsa21 harbors five miRNA genes. Importantly, miRNA expression profiling, miRNA RT-PCR, and miRNA in situ hybridization experiments demonstrated that all five Hsa21-derived miRNAs are over-expressed in brain and heart specimens from individuals with DS. We now hypothesize that the over-expression of the five Hsa21-derived miRNAs results in the under-expression of a number of important protein targets which contribute, in part, to the DS phenotype. Bioinformatic analyses demonstrated that several thousand proteins may be regulated by these miRNAs. Because combinatorial targeting of multiple miRNAs with a single mRNA may lead to a more pronounced down-regulation relative to mRNAs targeted by a few miRNAs, all of the Hsa21-derived miRNA/mRNA pairs were re-analyzed for the presence of multiple Hsa21-derived miRNA binding sites. This list of candidate targets was subsequently prioritized with respect to the potential clinical relevance of an individual target gene in playing a role in DS. Based on these criteria, we chose to investigate the methyl-CpG-binding protein (MeCP2), a transcription factor, as a potentially important Hsa21- derived miRNA target since its 34-untranslated region harbors at least one putative recognition site for all of the Has21-derived miRNAs. Additionally, MeCP2 is a provocative miRNA target since mutations in this gene contribute to Rett syndrome, a neurodevelopmental disorder that shares some of the neurologic abnormalities observed in DS. Our preliminary data now demonstrate that MeCP2 mRNA is a direct target of Hsa21-derived miR-155 and that MeCP2 is under-expressed in human fetal and adult DS brain specimens and in a mouse model of DS. As a consequence of attenuated MeCP2 expression, transcriptionally-activated and -silenced MeCP2 target genes are aberrantly regulated in these DS brain specimens. To begin to substantiate a causal role of Hsa21-derived miRNAs in DS, in vivo silencing of endogenous mature miR-155 expression by intra- ventricular injection of antagomir-155 resulted in the normalization of miR-155 and MeCP2 expression levels in the DS mouse brains. Taken together, these preliminary data suggest that improper repression of MeCP2, secondary to trisomic over-expression of miR-155, result in the aberrant regulation of MeCP2 target genes. This dysregulation subsequently results in the destabilization of important "regulatory circuits" that contribute, in part, to the cognitive defects that occur in DS individuals. PUBLIC HEALTH RELEVANCE: This project represents a novel line of inquiry regarding the molecular mechanisms of DS. This study will provide "proof of concept" that Hsa21-derived miRNAs inhibit the expression of critical regulatory proteins, which in turn, results in aberrant expression of a number of factors critical for neurodevelopment. Our approach includes a comprehensive and multi-disciplinary approach and includes human tissues, cell lines, and a DS mouse model. Our project will define miRNA/mRNA targets responsible for DS and will potentially lead to novel therapeutic strategies to treat DS individuals in the perinatal period to change the course of pathogenesis.
描述(由申请人提供):唐氏综合征(DS)的染色体异常是由人类21号染色体(Hsa21)部分的三倍复制引起的,但这种染色体异常如何导致DS表型尚不清楚。目前的提案将直接解决这一问题,重点是一类新的内源性基因调控因子,microRNAs (miRNAs)。mirna通常被认为是基因表达的负调控因子,通过碱基配对到蛋白质编码mRNA转录物中的互补序列来抑制翻译和/或促进信使RNA (mRNA)降解。我们最近的生物信息学分析证实Hsa21含有5个miRNA基因。重要的是,miRNA表达谱、miRNA RT-PCR和miRNA原位杂交实验表明,所有五种hsa21衍生的miRNA在DS患者的大脑和心脏标本中都过表达。我们现在假设,五种hsa21衍生的mirna的过度表达导致了一些重要蛋白靶点的低表达,这些蛋白靶点在一定程度上导致了DS表型。生物信息学分析表明,这些mirna可能调控数千种蛋白质。由于单一mRNA组合靶向多个miRNA可能导致相对于少数miRNA靶向的mRNA更明显的下调,因此重新分析所有hsa21衍生的miRNA/mRNA对是否存在多个hsa21衍生的miRNA结合位点。该候选靶点列表随后根据单个靶基因在退行性椎体滑移中发挥作用的潜在临床相关性进行了优先排序。基于这些标准,我们选择研究甲基cpg结合蛋白(MeCP2),一种转录因子,作为一个潜在的重要Hsa21衍生的miRNA靶标,因为它的34个未翻译区域包含至少一个对所有has21衍生的miRNA的假定识别位点。此外,MeCP2是一个具有争议性的miRNA靶点,因为该基因的突变会导致Rett综合征,这是一种神经发育障碍,在DS中观察到一些神经异常。我们现在的初步数据表明,MeCP2 mRNA是hsa21衍生的miR-155的直接靶点,MeCP2在人胎儿和成人DS脑标本以及DS小鼠模型中表达不足。由于MeCP2表达减弱,转录激活和沉默的MeCP2靶基因在这些DS脑标本中被异常调控。为了开始证实hsa21来源的mirna在DS中的因果作用,通过心室内注射antagomir-155在体内沉默内源性成熟miR-155的表达,导致DS小鼠大脑中miR-155和MeCP2表达水平正常化。综上所述,这些初步数据表明,继发于三体过表达miR-155的对MeCP2的不当抑制导致了MeCP2靶基因的异常调控。这种失调随后导致重要“调节回路”的不稳定,这在一定程度上导致了退行性痴呆患者的认知缺陷。公共卫生相关性:这个项目代表了关于退行性痴呆的分子机制的一个新的研究方向。这项研究将提供“概念证明”,即hsa21衍生的mirna抑制关键调节蛋白的表达,这反过来又导致许多对神经发育至关重要的因子的异常表达。我们的方法包括全面和多学科的方法,包括人体组织,细胞系和DS小鼠模型。我们的项目将确定与DS有关的miRNA/mRNA靶点,并可能导致新的治疗策略,以治疗围产期的DS个体,从而改变发病过程。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TERRY S ELTON其他文献
TERRY S ELTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TERRY S ELTON', 18)}}的其他基金
Novel Topoisomerase II alpha isoform as a drug resistance determinant
新型拓扑异构酶 II α 亚型作为耐药决定因素
- 批准号:
10297850 - 财政年份:2018
- 资助金额:
$ 22.7万 - 项目类别:
Novel Topoisomerase II alpha isoform as a drug resistance determinant
新型拓扑异构酶 II α 亚型作为耐药决定因素
- 批准号:
10057231 - 财政年份:2018
- 资助金额:
$ 22.7万 - 项目类别:
Novel Topoisomerase II alpha isoform as a drug resistance determinant
新型拓扑异构酶 II α 亚型作为耐药决定因素
- 批准号:
10531227 - 财政年份:2018
- 资助金额:
$ 22.7万 - 项目类别:
Training in Congenital and Acquired Heart Disease
先天性和后天性心脏病培训
- 批准号:
7762296 - 财政年份:2009
- 资助金额:
$ 22.7万 - 项目类别:
Training in Congenital and Acquired Heart Disease
先天性和后天性心脏病培训
- 批准号:
8126209 - 财政年份:2009
- 资助金额:
$ 22.7万 - 项目类别:
Training in Congenital and Acquired Heart Disease
先天性和后天性心脏病培训
- 批准号:
7939687 - 财政年份:2009
- 资助金额:
$ 22.7万 - 项目类别:
Human Angiotensin II Receptor Gene Regulation
人血管紧张素 II 受体基因调控
- 批准号:
6436185 - 财政年份:1992
- 资助金额:
$ 22.7万 - 项目类别:
Human Angiotensin II Receptor Gene Regulation
人血管紧张素 II 受体基因调控
- 批准号:
6839442 - 财政年份:1992
- 资助金额:
$ 22.7万 - 项目类别:
相似国自然基金
3'-甲氧基葛根素生物合成途径中关键甲基转移酶基因的克隆与功能分析
- 批准号:31300258
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
晚期妊娠维持和抑制早产中cAMP信号活化PR的作用机制研究
- 批准号:81300507
- 批准年份:2013
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
3'-UTR单核苷酸多态性影响CYP8B1基因表达致胆囊胆固醇结石形成的机制研究
- 批准号:81370561
- 批准年份:2013
- 资助金额:70.0 万元
- 项目类别:面上项目
异源杂交多倍化鲫鲤特有性状的转录组及后转录组水平变化规律研究
- 批准号:31360514
- 批准年份:2013
- 资助金额:54.0 万元
- 项目类别:地区科学基金项目
HIF基因3'UTR区SNP参与胰腺癌HIF-1α表达调控的分子机制及功能研究
- 批准号:81302082
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
鼻咽癌转移相关通路分子的microRNA调控机制及3'UTR区可变剪切的作用研究
- 批准号:81372886
- 批准年份:2013
- 资助金额:70.0 万元
- 项目类别:面上项目
小鼠精原干细胞中APA位点研究及3'UTR使用频率数据库构建
- 批准号:31301085
- 批准年份:2013
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目














{{item.name}}会员




